相关实验视频

Updated: Jun 20, 2025

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

抗素缺乏症:在60岁后,我们还需要了解更多关于肺部的信息

Robert A Stockley¹, David G Parr²

¹Lung Investigation Unit, Medicine - University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Edgbaston, UK.

ERJ open research

|July 23, 2024

概括

由于患者表型和增强疗法效果的多样性,阿尔法-1抗素缺乏肺部疾病的管理是复杂的. 需要进一步的研究来了解真正的自然历史,并改善患者的护理.

科学领域:

肺部病理学肺部病理学
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

在α-1抗素缺乏症 (AATD) 肺部疾病研究中,研究重点是增强疗法的效果.
疾病的复杂性,自然史和表型变异使患者管理和研究解释复杂化.
现有的注册表缺乏一致的评估,可能会扭曲与AATD相关的肺部疾病的感知自然史.

研究的目的:

为了应对AATD患者管理和研究设计的挑战.
讨论在AATD中评估患者变异性的复杂性.
为未来对AATD自然历史和治疗策略的研究提供指导.

主要方法:

对AATD肺部疾病现有文献的综述.
分析患者表型和可变性评估中的挑战.
讨论对研究设计和结果解释的影响.

主要成果:

由于表型复杂性和增强疗法的影响,AATD肺部疾病的自然史尚未完全理解.
目前的研究设计在充分评估AATD方面面临挑战,特别是在传统COPD结果方面.
目前的注册表中缺乏一致的,深入的患者评估.

结论:

了解AATD肺部疾病的真实自然史需要解决患者的变异性和增强疗法的影响.
由于AATD的稀有性和异质性,新的治疗策略和增强疗法的疗效评估具有挑战性.
通过标准化评估进行进一步的研究对于推进AATD患者护理和治疗开发至关重要.

更多相关视频

Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling

Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling

Published on: February 12, 2019

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

相关概念视频

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...